开云app官网登录入口网页版-官方正版

#生存期#

350篇内容 | 4087人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1378348, encodeId=5f9013e834886, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=Lancet子刊：南方医科大学李国新等合作团队开发了一种深度学习模型，可实时、准确预测腹膜复发风险和无病生存期, objectType=article, longId=739121, objectId=3bd8e3912193, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3bd8e3912193, replyNumber=0, likeNumber=101, createdTime=2022-09-14, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3bd8e3912193, moduleTitle=Lancet子刊：南方医科大学李国新等合作团队开发了一种深度学习模型，可实时、准确预测腹膜复发风险和无病生存期, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=3bd8e3912193)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378347, encodeId=3df413e834796, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=ESMO 2022：双艾组合卡瑞利珠单抗联合阿帕替尼可显著改善不可切除HCC的生存期（SHR-1210-III-310研究）, objectType=article, longId=739071, objectId=dd97e3907119, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dd97e3907119, replyNumber=0, likeNumber=91, createdTime=2022-09-13, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dd97e3907119, moduleTitle=ESMO 2022：双艾组合卡瑞利珠单抗联合阿帕替尼可显著改善不可切除HCC的生存期（SHR-1210-III-310研究）, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=dd97e3907119)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378346, encodeId=e42713e834691, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=Clin Cancer Res：纳武单抗加用多西他赛可显著延长ICI初治NSCLC患者的生存期, objectType=article, longId=737804, objectId=dbf0e37804ff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dbf0e37804ff, replyNumber=0, likeNumber=171, createdTime=2022-09-06, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dbf0e37804ff, moduleTitle=Clin Cancer Res：纳武单抗加用多西他赛可显著延长ICI初治NSCLC患者的生存期, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=dbf0e37804ff)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378345, encodeId=471d13e83457b, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=乳腺癌亚型与脑转移的发生率、放疗情况和生存期关系如何？JAMA Netw Open发表结果一一解答, objectType=article, longId=737677, objectId=96d1e376771d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=96d1e376771d, replyNumber=0, likeNumber=91, createdTime=2022-09-04, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=96d1e376771d, moduleTitle=乳腺癌亚型与脑转移的发生率、放疗情况和生存期关系如何？JAMA Netw Open发表结果一一解答, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=96d1e376771d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378344, encodeId=39e913e834405, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=Nature Medicine：黑猩猩腺病毒+自扩增mRNA癌症疫苗，在临床试验中延长晚期实体瘤患者总生存期, objectType=article, longId=736369, objectId=39abe36369ff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=39abe36369ff, replyNumber=0, likeNumber=94, createdTime=2022-08-21, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=39abe36369ff, moduleTitle=Nature Medicine：黑猩猩腺病毒+自扩增mRNA癌症疫苗，在临床试验中延长晚期实体瘤患者总生存期, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=39abe36369ff)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378343, encodeId=5c5613e834334, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=Euro Radio：用于预测食管癌患者无病生存期和总生存期的MR放射组学模型, objectType=article, longId=736296, objectId=0f70e36296c7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0f70e36296c7, replyNumber=0, likeNumber=104, createdTime=2022-08-21, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0f70e36296c7, moduleTitle=Euro Radio：用于预测食管癌患者无病生存期和总生存期的MR放射组学模型, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=0f70e36296c7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378342, encodeId=8ef313e834237, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=European Radiology：预测生存期的最佳反应时间点与肝细胞癌TACE术后的肿瘤负荷有关, objectType=article, longId=736018, objectId=8b06e36018f7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8b06e36018f7, replyNumber=0, likeNumber=111, createdTime=2022-08-18, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8b06e36018f7, moduleTitle=European Radiology：预测生存期的最佳反应时间点与肝细胞癌TACE术后的肿瘤负荷有关, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=8b06e36018f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378341, encodeId=e39f13e83415e, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=肿瘤医生总结：生存期超过30年的癌症患者，一般有这3个特点！, objectType=article, longId=735567, objectId=ea29e355672a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ea29e355672a, replyNumber=0, likeNumber=137, createdTime=2022-08-12, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ea29e355672a, moduleTitle=肿瘤医生总结：生存期超过30年的癌症患者，一般有这3个特点！, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=ea29e355672a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378340, encodeId=31d313e8340ff, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=国际前沿研究 | 中位生存期只有15个月，丘脑胶质母细胞瘤患者的未来在哪里？, objectType=article, longId=735064, objectId=b171e3506406, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b171e3506406, replyNumber=0, likeNumber=107, createdTime=2022-08-08, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b171e3506406, moduleTitle=国际前沿研究 | 中位生存期只有15个月，丘脑胶质母细胞瘤患者的未来在哪里？, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=b171e3506406)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378339, encodeId=cffd13e833934, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=NEJM：ADC药物效果惊艳，延长晚期乳腺癌患者无进展生存期50%, objectType=article, longId=728906, objectId=8ed1e2890609, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8ed1e2890609, replyNumber=0, likeNumber=111, createdTime=2022-06-10, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8ed1e2890609, moduleTitle=NEJM：ADC药物效果惊艳，延长晚期乳腺癌患者无进展生存期50%, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=8ed1e2890609)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378337, encodeId=a6af13e8337b8, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=2022 ASCO：基于查尔森合并症指数（CCI）预测急性早幼粒细胞白血病（APL）的早期死亡率和总生存期, objectType=article, longId=728460, objectId=e715e2846054, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e715e2846054, replyNumber=0, likeNumber=140, createdTime=2022-06-03, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e715e2846054, moduleTitle=2022 ASCO：基于查尔森合并症指数（CCI）预测急性早幼粒细胞白血病（APL）的早期死亡率和总生存期, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=e715e2846054)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378338, encodeId=547713e83389d, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=ASCO2022: 中间临床终点作为转移性激素敏感前列腺癌患者总生存期替代指标的科学性分析, objectType=article, longId=728378, objectId=9bf0e283789c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9bf0e283789c, replyNumber=0, likeNumber=142, createdTime=2022-06-02, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9bf0e283789c, moduleTitle=ASCO2022: 中间临床终点作为转移性激素敏感前列腺癌患者总生存期替代指标的科学性分析, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=9bf0e283789c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378336, encodeId=5b1c13e8336ef, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=HAEMATOLOGICA：PET-CT状态对接受自体干细胞移植的复发性滤泡性淋巴瘤患者无进展生存期的影响, objectType=article, longId=727501, objectId=ccafe275011b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ccafe275011b, replyNumber=0, likeNumber=77, createdTime=2022-05-23, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ccafe275011b, moduleTitle=HAEMATOLOGICA：PET-CT状态对接受自体干细胞移植的复发性滤泡性淋巴瘤患者无进展生存期的影响, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=ccafe275011b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378335, encodeId=134a13e8335ab, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=BMJ：信迪利单抗联合化疗一线治疗可显著延长晚期/转移性食管鳞癌患者的生存期, objectType=article, longId=725552, objectId=9947e255526a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9947e255526a, replyNumber=0, likeNumber=138, createdTime=2022-04-28, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9947e255526a, moduleTitle=BMJ：信迪利单抗联合化疗一线治疗可显著延长晚期/转移性食管鳞癌患者的生存期, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=9947e255526a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378333, encodeId=b86513e83336f, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=AACR重磅之INSIGHT研究：特泊替尼+吉非替尼联合治疗显著改善了伴有MET扩增的EGFR突变阳性NSCLC患者无进展生存期和总生存期, objectType=article, longId=723968, objectId=3207e2396893, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3207e2396893, replyNumber=0, likeNumber=81, createdTime=2022-04-12, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3207e2396893, moduleTitle=AACR重磅之INSIGHT研究：特泊替尼+吉非替尼联合治疗显著改善了伴有MET扩增的EGFR突变阳性NSCLC患者无进展生存期和总生存期, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=3207e2396893)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378332, encodeId=03b113e83326b, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=AACR重磅之KEYNOTE-042：帕博丽珠单抗持续延长了中国晚期/转移性PD-L1阳性NSCLC患者的生存期——Keynote-042中国研究的4年随访数据结果, objectType=article, longId=723967, objectId=4b52e23967b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4b52e23967b8, replyNumber=0, likeNumber=87, createdTime=2022-04-12, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4b52e23967b8, moduleTitle=AACR重磅之KEYNOTE-042：帕博丽珠单抗持续延长了中国晚期/转移性PD-L1阳性NSCLC患者的生存期——Keynote-042中国研究的4年随访数据结果, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=4b52e23967b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378331, encodeId=b30e13e8331d3, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=BMJ：低剂量CT筛查对肺癌患者疾病分期及生存期的影响, objectType=article, longId=302266, objectId=ef6930226602, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ef6930226602, replyNumber=0, likeNumber=122, createdTime=2022-04-04, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ef6930226602, moduleTitle=BMJ：低剂量CT筛查对肺癌患者疾病分期及生存期的影响, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=ef6930226602)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378330, encodeId=fa3013e8330ce, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=npj Parkinsons Dis：中性粒细胞和淋巴细胞比值，可预测多系统萎缩的生存期, objectType=article, longId=301908, objectId=3d3a3019081d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3d3a3019081d, replyNumber=0, likeNumber=109, createdTime=2022-03-30, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3d3a3019081d, moduleTitle=npj Parkinsons Dis：中性粒细胞和淋巴细胞比值，可预测多系统萎缩的生存期, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=3d3a3019081d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378334, encodeId=f7c513e8334aa, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=III期临床研究CheckMate -816证实：纳武利尤单抗联合化疗作为可切除非小细胞肺癌患者新辅助治疗，可显著改善无事件生存期, objectType=article, longId=301595, objectId=0e1630159509, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0e1630159509, replyNumber=0, likeNumber=78, createdTime=2022-03-26, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0e1630159509, moduleTitle=III期临床研究CheckMate -816证实：纳武利尤单抗联合化疗作为可切除非小细胞肺癌患者新辅助治疗，可显著改善无事件生存期, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=0e1630159509)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378329, encodeId=3bb313e8329d5, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, objectTitle=JGABSMS：健康的行为、休闲活动和社交网络延长老年糖尿病患者的无残疾生存期, objectType=article, longId=301115, objectId=576430111506, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=576430111506, replyNumber=0, likeNumber=84, createdTime=2022-03-20, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=576430111506, moduleTitle=JGABSMS：健康的行为、休闲活动和社交网络延长老年糖尿病患者的无残疾生存期, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=576430111506)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

生存期

2020-05-29

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

Lancet子刊：南方医科大学李国新等合作团队开发了一种深度学习模型，可实时、准确预测腹膜复发风险和无病生存期

2022-09-14

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

ESMO 2022：双艾组合卡瑞利珠单抗联合阿帕替尼可显著改善不可切除HCC的生存期（SHR-1210-III-310研究）

2022-09-13

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

Clin Cancer Res：纳武单抗加用多西他赛可显著延长ICI初治NSCLC患者的生存期

2022-09-06

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

乳腺癌亚型与脑转移的发生率、放疗情况和生存期关系如何？JAMA Netw Open发表结果一一解答

2022-09-04

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

Nature Medicine：黑猩猩腺病毒+自扩增mRNA癌症疫苗，在临床试验中延长晚期实体瘤患者总生存期

2022-08-21

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

Euro Radio：用于预测食管癌患者无病生存期和总生存期的MR放射组学模型

2022-08-21

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

European Radiology：预测生存期的最佳反应时间点与肝细胞癌TACE术后的肿瘤负荷有关

2022-08-18

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

肿瘤医生总结：生存期超过30年的癌症患者，一般有这3个特点！

2022-08-12

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

国际前沿研究 | 中位生存期只有15个月，丘脑胶质母细胞瘤患者的未来在哪里？

2022-08-08

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

NEJM：ADC药物效果惊艳，延长晚期乳腺癌患者无进展生存期50%

2022-06-10

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

2022 ASCO：基于查尔森合并症指数（CCI）预测急性早幼粒细胞白血病（APL）的早期死亡率和总生存期

2022-06-03

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

ASCO2022: 中间临床终点作为转移性激素敏感前列腺癌患者总生存期替代指标的科学性分析

2022-06-02

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

HAEMATOLOGICA：PET-CT状态对接受自体干细胞移植的复发性滤泡性淋巴瘤患者无进展生存期的影响

2022-05-23

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

BMJ：信迪利单抗联合化疗一线治疗可显著延长晚期/转移性食管鳞癌患者的生存期

2022-04-28

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

AACR重磅之INSIGHT研究：特泊替尼+吉非替尼联合治疗显著改善了伴有MET扩增的EGFR突变阳性NSCLC患者无进展生存期和总生存期

2022-04-12

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

AACR重磅之KEYNOTE-042：帕博丽珠单抗持续延长了中国晚期/转移性PD-L1阳性NSCLC患者的生存期——Keynote-042中国研究的4年随访数据结果

2022-04-12

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

BMJ：低剂量CT筛查对肺癌患者疾病分期及生存期的影响

2022-04-04

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

npj Parkinsons Dis：中性粒细胞和淋巴细胞比值，可预测多系统萎缩的生存期

2022-03-30

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

III期临床研究CheckMate -816证实：纳武利尤单抗联合化疗作为可切除非小细胞肺癌患者新辅助治疗，可显著改善无事件生存期

2022-03-26

juliusluan78 (审核中...)

前往app查看评论内容

#生存期#

JGABSMS：健康的行为、休闲活动和社交网络延长老年糖尿病患者的无残疾生存期

2022-03-20

科室
- - 订阅+
  - 更多科室
工具
服务